The aim of this study is the safety and efficacy of mix vaccine to small metastases of kidney cancer.
By enrolling patients with small metastases of kidney cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of mix vaccine. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
Cancer institute of Fuda cancer hospital
Guangzhou, Guangdong, China
Relief degree of tumors
It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）
Time frame: 3 months
Progress free survival（PFS）
The duration from the beginning of treatment to cancer recurrence or progression
Time frame: 1 year
Overall survival（OS）
The duration from the beginning of treatment to patient death
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.